Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.40 |
| ▸ | ITGAL | P20701 | 2/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PPIA | P62937 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23355178 | 0.77 | ITGB2 (0.48) | ITGB2ICAM1ITGALPSMB1PSMB5 | |
| SCHEMBL7135256 | 0.72 | ITGB2 (0.53) | ITGB2ICAM1ITGALMEN1KMT2A | |
| SCHEMBL8402596 | 0.68 | SMN1; SMN2 (0.59) | ITGB2ICAM1ITGALPSMB1PSMB5 | |
| SCHEMBL8402593 | 0.68 | SMN1; SMN2 (0.59) | ITGB2ICAM1ITGALPSMB1PSMB5 | |
| SCHEMBL23355193 | 0.68 | ITGA4 (0.48) | ITGB2ICAM1ITGALLMNASMN1; SMN2 | |
| SCHEMBL551858 | 0.65 | ALB (0.47) | ITGB2ICAM1ITGALMEN1KMT2A | |
| SCHEMBL163483 | 0.65 | EPHX2 (0.53) | ITGB2ICAM1ITGALPSMB1PSMB5 | |
| SCHEMBL162523 | 0.65 | EPHX2 (0.53) | ITGB2ICAM1ITGALPSMB1PSMB5 | |
| SCHEMBL162522 | 0.65 | EPHX2 (0.53) | ITGB2ICAM1ITGALPSMB1PSMB5 | |
| SCHEMBL28025198 | 0.64 | RAB9A (0.51) | MEN1KMT2ANPC1RAB9APPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093241-B2 | Acid amide derivatives, process for their production and pesticides containing them | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20100093707-A1 | ACID AMIDE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PESTICIDES CONTAINING THEM | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-7683096-B2 | Acid amide derivatives, process for producing these, and pest control agent containing these | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20040254237-A1 | Acid amide derivatives, process for producing these, and pest agent containing these | ISHIHARA SANGYO KAISHA LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1428817-A1 | ACID AMIDE DERIVATIVES, PROCESS FOR PRODUCING THESE, AND PEST CONTROL AGENT CONTAINING THESE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093707-A1 | ACID AMIDE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PESTICIDES CONTAINING THEM | NAA15, SAP18, CYP2C18 | ITGB2 4841/4885ICAM1 4766/4885ITGAL 4708/4885 |
| US-20040254237-A1 | Acid amide derivatives, process for producing these, and pest agent containing these | NAA15, CBR3, CBR1 | ITGB2 4711/4885ICAM1 4642/4885ITGAL 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.